{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:52:08Z","timestamp":1778586728847,"version":"3.51.4"},"reference-count":93,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Hospitalizations for COVID-19 dramatically increase with age. This is likely because of increases in fragility across biological repair systems and a weakened immune system, including loss of the cardiorenal protective arm of the renin--angiotensin system (RAS), composed of angiotensin-converting enzyme-2 (ACE2)\/angiotensin-(1--7) [Ang-(1--7)] and its actions through the Mas receptor. The purpose of this review is to explore how cardiac ACE2 changes with age, cardiac diseases, comorbid conditions and pharmaceutical regimens in order to shed light on a potential hormonal unbalance facilitating SARs-CoV-2 vulnerabilities in older adults.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Increased <jats:italic toggle=\"yes\">ACE2<\/jats:italic> gene expression has been reported in human hearts with myocardial infarction, cardiac remodeling and heart failure. We also found ACE2 mRNA in atrial appendage tissue from cardiac surgical patients to be positively associated with age, elevated by certain comorbid conditions (e.g. COPD and previous stroke) and increased in conjunction with patients\u2019 chronic use of antithrombotic agents and thiazide diuretics but not drugs that block the renin--angiotensin system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Cardiac ACE2 may have bifunctional roles in COVID-19 as ACE2 not only mediates cellular susceptibility to SARS-CoV-2 infection but also protects the heart via the ACE2\/Ang-(1--7) pathway. Linking tissue ACE2 from cardiac surgery patients to their comorbid conditions and medical regimens provides a unique latform to address the influence that altered expression of the ACE2\/Ang-(1\u20137)\/Mas receptor axis might have on SARs-CoV-2 vulnerability in older adults.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aco.0000000000000965","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T01:04:05Z","timestamp":1614387845000},"page":"187-198","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities"],"prefix":"10.1097","volume":"34","author":[{"given":"Hao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Anesthesiology"},{"name":"Department of Internal Medicine, Section of Molecular Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit K.","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuming","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal D.","family":"Kon","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos M.","family":"Ferrario","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Wake Forest School of Medicine, Winston Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leanne","family":"Groban","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology"},{"name":"Department of Internal Medicine, Section of Molecular Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"R1-20250601","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R2-20250601","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1111\/trf.16130","article-title":"Association of ABO blood group and secretor phenotype with severe COVID-19","volume":"60","author":"Valenti","year":"2020","journal-title":"Transfusion"},{"key":"R3-20250601","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa2020283","article-title":"Genomewide association study of severe Covid-19 with respiratory failure","volume":"383","author":"Ellinghaus","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-20250601","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1038\/s41467-020-19623-x","article-title":"Associations between blood type and COVID-19 infection, intubation, and death","volume":"11","author":"Zietz","year":"2020","journal-title":"Nat Commun"},{"key":"R5-20250601","doi-asserted-by":"crossref","first-page":"e0239508","DOI":"10.1371\/journal.pone.0239508","article-title":"The association between ABO blood group and SARS-CoV-2 infection: a meta-analysis","volume":"15","author":"Golinelli","year":"2020","journal-title":"PLoS One"},{"key":"R6-20250601","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0022-2828(03)00177-9","article-title":"Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins","volume":"35","author":"Donoghue","year":"2003","journal-title":"J Mol Cell Cardiol"},{"key":"R7-20250601","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"R8-20250601","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"key":"R9-20250601","doi-asserted-by":"crossref","first-page":"841","DOI":"10.15585\/mmwr.mm6926e3","article-title":"Characteristics of adult outpatients and inpatients with COVID-19-11 Academic Medical Centers, United States, March-May 2020","volume":"69","author":"Tenforde","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R10-20250601","article-title":"COVID-19 severity is predicted by earlier evidence of accelerated aging","author":"Kuo","year":"2020","journal-title":"medRxiv"},{"key":"R11-20250601","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/gerona\/glaa169","article-title":"ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank","volume":"75","author":"Kuo","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R12-20250601","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s13054-020-03223-8","article-title":"Blood type A associates with critical COVID-19 and death in a Swedish cohort","volume":"24","author":"Hultstr\u00f6m","year":"2020","journal-title":"Crit Care"},{"key":"R13-20250601","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.78.11.7124","article-title":"The aging process","volume":"78","author":"Harman","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-20250601","doi-asserted-by":"crossref","first-page":"101154","DOI":"10.1016\/j.arr.2020.101154","article-title":"Fight to the bitter end: DNA repair and aging","volume":"64","author":"Chen","year":"2020","journal-title":"Ageing Res Rev"},{"key":"R15-20250601","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.HYP.25.3.437","article-title":"Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging","volume":"25","author":"Inserra","year":"1995","journal-title":"Hypertension"},{"key":"R16-20250601","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bcp.2009.06.018","article-title":"Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats","volume":"78","author":"Santos","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"R17-20250601","doi-asserted-by":"crossref","first-page":"H1351","DOI":"10.1152\/ajpheart.00393.2007","article-title":"Protective effect of long-term angiotensin II inhibition","volume":"293","author":"Basso","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R18-20250601","doi-asserted-by":"crossref","first-page":"H15","DOI":"10.1152\/ajpheart.00459.2014","article-title":"Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition","volume":"309","author":"de Cavanagh","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"(11 Pt 1)","key":"R19-20250601","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0895-7061(98)00152-6","article-title":"Biomolecular changes in the aging myocardium: the effect of enalapril","volume":"11","author":"Ferder","year":"1998","journal-title":"Am J Hypertens"},{"key":"R20-20250601","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1096\/fj.02-0063fje","article-title":"Enalapril and losartan attenuate mitochondrial dysfunction in aged rats","volume":"17","author":"de Cavanagh","year":"2003","journal-title":"FASEB J"},{"key":"R21-20250601","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.exger.2008.08.007","article-title":"Renin-angiotensin system inhibitors protect against age-related changes in rat liver mitochondrial DNA content and gene expression","volume":"43","author":"de Cavanagh","year":"2008","journal-title":"Exp Gerontol"},{"key":"R22-20250601","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mam.2004.02.006","article-title":"Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging","volume":"25","author":"de Cavanagh","year":"2004","journal-title":"Mol Aspects Med"},{"key":"R23-20250601","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.arr.2010.02.001","article-title":"Protein homeostasis and aging: the importance of exquisite quality control","volume":"10","author":"Koga","year":"2011","journal-title":"Ageing Res Rev"},{"key":"R24-20250601","first-page":"1","article-title":"A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin","author":"Justice","year":"2020","journal-title":"Geroscience"},{"key":"R25-20250601","article-title":"Observational study of Metformin and risk of mortality in patients hospitalized with Covid-19","author":"Bramante","year":"2020","journal-title":"medRxiv"},{"key":"R26-20250601","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.tem.2020.09.003","article-title":"Sexual dimorphism of coronavirus 19 morbidity and lethality","volume":"31","author":"Brandi","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"R27-20250601","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/cvr\/cvaa284","article-title":"Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities","volume":"116","author":"Bienvenu","year":"2020","journal-title":"Cardiovasc Res"},{"key":"R28-20250601","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1590\/0001-3765201720160487","article-title":"Immune system dysfunction in the elderly","volume":"89","author":"Fuentes","year":"2017","journal-title":"An Acad Bras Cienc"},{"key":"R29-20250601","first-page":"382","article-title":"The 2009\u200aA\/H1N1 pandemic influenza and the nursing home","volume":"93","author":"Gravenstein","year":"2010","journal-title":"Med Health R I"},{"key":"R30-20250601","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"R31-20250601","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11906-017-0708-3","article-title":"Novel cardiac intracrine mechanisms based on Ang-(1-12)\/chymase axis require a revision of therapeutic approaches in human heart disease","volume":"19","author":"Reyes","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"R32-20250601","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-030-22696-1_6","article-title":"Angiotensin-(1-7) and the heart","author":"Ferrario","year":"2019","journal-title":"Angiotensin-(1-7): a comprehensive review"},{"issue":"(3 Pt 2)","key":"R33-20250601","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/01.HYP.30.3.535","article-title":"Counterregulatory actions of angiotensin-(1-7)","volume":"30","author":"Ferrario","year":"1997","journal-title":"Hypertension"},{"key":"R34-20250601","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J Biol Chem"},{"key":"R35-20250601","doi-asserted-by":"crossref","first-page":"594361","DOI":"10.1155\/2012\/594361","article-title":"Protective role of the ACE2\/Ang-(1-9) axis in cardiovascular remodeling","volume":"2012","author":"Ocaranza","year":"2012","journal-title":"Int J Hypertens"},{"key":"R36-20250601","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1139\/y02-021","article-title":"ACEH\/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors","volume":"80","author":"Turner","year":"2002","journal-title":"Can J Physiol Pharmacol"},{"key":"R37-20250601","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1152\/ajplung.00498.2016","article-title":"Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin\/BKB1R axis and facilitates LPS-induced neutrophil infiltration","volume":"314","author":"Sodhi","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R38-20250601","doi-asserted-by":"crossref","first-page":"823193","DOI":"10.1155\/2012\/823193","article-title":"Targeting the ACE2 and apelin pathways are novel therapies for heart failure: opportunities and challenges","volume":"2012","author":"Kazemi-Bajestani","year":"2012","journal-title":"Cardiol Res Pract"},{"key":"R39-20250601","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1566524019666191028122559","article-title":"Dynorphins in development and disease: implications for cardiovascular disease","volume":"20","author":"Cissom","year":"2020","journal-title":"Curr Mol Med"},{"key":"R40-20250601","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0895-7061(97)00400-7","article-title":"Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects","volume":"11","author":"Ferrario","year":"1998","journal-title":"Am J Hypertens"},{"key":"R41-20250601","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0895-7061(02)02268-9","article-title":"Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension","volume":"15","author":"Ferrario","year":"2002","journal-title":"Am J Hypertens"},{"key":"R42-20250601","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00004872-199606000-00017","article-title":"Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension","volume":"14","author":"Luque","year":"1996","journal-title":"J Hypertens"},{"key":"R43-20250601","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0091270006294280","article-title":"Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects","volume":"47","author":"Schindler","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R44-20250601","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2217\/14796678.4.4.357","article-title":"Olmesartan for the treatment of arterial hypertension","volume":"4","author":"Schindler","year":"2008","journal-title":"Future Cardiol"},{"key":"R45-20250601","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.tem.2004.03.001","article-title":"ACE2, a new regulator of the renin-angiotensin system","volume":"15","author":"Burrell","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"R46-20250601","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.ki.5000321","article-title":"ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1-7)","volume":"70","author":"Chappel","year":"2006","journal-title":"Kidney Int"},{"key":"R47-20250601","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"R48-20250601","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/01.HYP.0000196268.08909.fb","article-title":"Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation","volume":"47","author":"Ferrario","year":"2006","journal-title":"Hypertension"},{"key":"R49-20250601","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1113\/expphysiol.2007.040048","article-title":"The discovery of ACE2 and its role in acute lung injury","volume":"93","author":"Penninger","year":"2008","journal-title":"Exp Physiol"},{"key":"R50-20250601","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-2-19","article-title":"ACE2 gene expression is up-regulated in the human failing heart","volume":"2","author":"Goulter","year":"2004","journal-title":"BMC Med"},{"key":"R51-20250601","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1172\/JCI0215490","article-title":"The plasma kallikrein-kinin system counterbalances the renin-angiotensin system","volume":"109","author":"Schmaier","year":"2002","journal-title":"J Clin Invest"},{"key":"R52-20250601","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13168","article-title":"Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation","volume":"19","author":"Chen","year":"2020","journal-title":"Aging Cell"},{"key":"R53-20250601","article-title":"Age is associated with increased expression of pattern recognition receptor genes and ACE2, the receptor for SARS-COV-2: implications for the epidemiology of COVID-19 disease","author":"Bickler","year":"2020","journal-title":"bioRxiv"},{"key":"R54-20250601","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13613-019-0529-4","article-title":"Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study","volume":"9","author":"Schouten","year":"2019","journal-title":"Ann Intensive Care"},{"key":"R55-20250601","article-title":"Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation","author":"Baker","year":"2020","journal-title":"medRxiv"},{"key":"R56-20250601","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect Dis Poverty"},{"key":"R57-20250601","doi-asserted-by":"crossref","first-page":"481","DOI":"10.21037\/atm.2020.03.61","article-title":"A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection","volume":"8","author":"Dai","year":"2020","journal-title":"Ann Transl Med"},{"key":"R58-20250601","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jacc.2020.06.007","article-title":"Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection","volume":"76","author":"Lala","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R59-20250601","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cjca.2020.05.018","article-title":"Cardiovascular implications of the COVID-19 pandemic: a global perspective","volume":"36","author":"Boukhris","year":"2020","journal-title":"Can J Cardiol"},{"key":"R60-20250601","doi-asserted-by":"crossref","first-page":"582399","DOI":"10.3389\/fcvm.2020.582399","article-title":"Molecular basis of cardiac and vascular injuries associated with COVID-19","volume":"7","author":"Hachim","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"R62-20250601","doi-asserted-by":"crossref","first-page":"e28501","DOI":"10.1371\/journal.pone.0028501","article-title":"Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue","volume":"6","author":"Ahmad","year":"2011","journal-title":"PLoS One"},{"key":"R63-20250601","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/cvr\/cvaa086","article-title":"Inside the heart of COVID-19","volume":"116","author":"Ad\u00e3o","year":"2020","journal-title":"Cardiovasc Res"},{"key":"R64-20250601","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc Res"},{"key":"R65-20250601","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ajem.2020.04.048","article-title":"Cardiovascular complications in COVID-19","volume":"38","author":"Long","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R66-20250601","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jchf.2020.03.004","article-title":"COVID-19 illness and heart failure: a missing link?","volume":"8","author":"Mehra","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R67-20250601","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R68-20250601","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R69-20250601","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"R70-20250601","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"R71-20250601","doi-asserted-by":"crossref","first-page":"104906","DOI":"10.1016\/j.phrs.2020.104906","article-title":"COVID-19, hypertension and cardiovascular diseases: should we change the therapy?","volume":"158","author":"Tadic","year":"2020","journal-title":"Pharmacol Res"},{"key":"R72-20250601","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"R73-20250601","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Ishiyama","year":"2004","journal-title":"Hypertension"},{"key":"R74-20250601","first-page":"625","article-title":"Effects of angiotensin converting enzyme inhibitor on the expression of angiotensin converting enzyme 2 in atrium of patients with atrial fibrillation","volume":"35","author":"Hu","year":"2007","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"R75-20250601","doi-asserted-by":"crossref","first-page":"H1013","DOI":"10.1152\/ajpheart.00068.2005","article-title":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats","volume":"289","author":"Igase","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R76-20250601","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/01.HYP.0000237862.94083.45","article-title":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat","volume":"48","author":"Ocaranza","year":"2006","journal-title":"Hypertension"},{"key":"R77-20250601","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"R78-20250601","doi-asserted-by":"crossref","first-page":"e2016877118","DOI":"10.1073\/pnas.2016877118","article-title":"A data-driven approach to identify risk profiles and protective drugs in COVID-19","volume":"118","author":"Cipp\u00e0","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R79-20250601","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"R80-20250601","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"R81-20250601","doi-asserted-by":"crossref","first-page":"106805","DOI":"10.1016\/j.vph.2020.106805","article-title":"RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies","volume":"135","year":"2020","journal-title":"Vascul Pharmacol"},{"key":"R82-20250601","article-title":"Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: a meta-analysis","author":"Zhang","year":"2020","journal-title":"J Med Virol"},{"key":"R83-20250601","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40264-020-00994-5","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian Cohort Study of 43,000 patients","volume":"43","author":"Trifir\u00f2","year":"2020","journal-title":"Drug Saf"},{"key":"R84-20250601","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1093\/cvr\/cvaa325","article-title":"COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial","volume":"116","author":"Mancia","year":"2020","journal-title":"Cardiovasc Res"},{"key":"R85-20250601","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2119\/molmed.2009.00160","article-title":"ACE2 activation promotes anti-thrombotic activity","volume":"16","author":"Fraga-Silva","year":"2010","journal-title":"Mol Med"},{"key":"R86-20250601","doi-asserted-by":"crossref","first-page":"15886","DOI":"10.1073\/pnas.1001253107","article-title":"Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells","volume":"107","author":"Zhang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R87-20250601","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1161\/ATVBAHA.108.164715","article-title":"Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis","volume":"28","author":"Dong","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R88-20250601","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/ATVBAHA.110.221614","article-title":"Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-\/- mice","volume":"31","author":"Thatcher","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R89-20250601","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis","volume":"169","author":"Sim\u00f5es e Silva","year":"2013","journal-title":"Br J Pharmacol"},{"key":"R90-20250601","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"R91-20250601","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1111\/bph.15094","article-title":"A rational roadmap for SARS-CoV-2\/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29","volume":"177","author":"Alexander","year":"2020","journal-title":"Br J Pharmacol"},{"key":"R92-20250601","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jash.2007.10.005","article-title":"Differential effect of low dose thiazides on the renin angiotensin system in genetically hypertensive and normotensive rats","volume":"2","author":"Jessup","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"R93-20250601","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2174\/138161208783877947","article-title":"Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides","volume":"14","author":"Supuran","year":"2008","journal-title":"Curr Pharm Des"},{"key":"R94-20250601","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12575-020-00124-6","article-title":"Application of system biology to explore the association of neprilysin, angiotensin-converting enzyme 2 (ACE2), and carbonic anhydrase (CA) in pathogenesis of SARS-CoV-2","volume":"22","author":"Zolfaghari Emameh","year":"2020","journal-title":"Biol Proced Online"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000000965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T22:12:04Z","timestamp":1748815924000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000000965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000000965","relation":{},"ISSN":["0952-7907","1473-6500"],"issn-type":[{"value":"0952-7907","type":"print"},{"value":"1473-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}